NEW YORK (GenomeWeb) – Interleukin Genetics on Monday announced that it would suspend its genetic testing program for severe gum disease and elevated systemic inflammation over the next 60 days after it was unable to defer a debt payment.

The Waltham, Massachusetts-based firm said it would also lay off five employees, or 63 percent of its current workforce. The decisions come as the company pursues strategic alternatives, Interleukin CEO Mark Carbeau said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.